Introduction {#sec1}
============

Gestational diabetes mellitus (GDM) is defined as glucose intolerance that occurs during pregnancy. The GDM is the most prevalent metabolic disorder during pregnancy with prevalence between 9.3% and 25.5%, which is attributed mainly to obesity, older maternal age, and a sedentary lifestyle \[[@B1]\]. GDM results in significant perinatal mortalities and comorbidities. Pregnant women complicated with GDM tend to have increasing risk of obesity, diabetes mellitus (DM), and cardiovascular disease. The underlying factors leading to the development of GDM are difficult to determine, and may involve a combination of diverse environmental, genetic, and epigenetic factors. An increasing amount of evidence points to a connection between genetics and GDM \[[@B2]\].

Insulin-like growth factor 2 mRNA-binding protein 2 (*IGF2BP2*) is part of the family of mRNA-binding proteins regulating insulin-like growth factor 2 (*IGF2*) translation. *IGF2BP2* is located on chromosome 3q27. A previous animal study showed that *IGF2* is involved in pancreatic function \[[@B3]\]. Several studies have reported that the polymorphisms in *IGF2BP2* is associated with reduced β-cell function \[[@B4],[@B5]\] and risk of DM \[[@B6]\]. Previous studies revealed that 2.6--70% of women with a history of GDM will develop DM 28 years postpartum \[[@B7]\], and women with a family history of DM may be predisposed to an increased risk of GDM \[[@B8]\]. GDM may share the same risk factors and genetic susceptibilities with DM that indicates that *IGF2BP2* gene polymorphism may also be associated with GDM.

To date, researchers investigated the association between three *IGF2BP2* polymorphisms (rs4402960, rs1470579, rs11705701) and GDM. There was no evidence of the association between *IGF2BP2* rs1470579 or rs11705701 and risk of GDM \[[@B9],[@B10]\]. Recently, the association between *IGF2BP2* rs4402960 polymorphism and risk of GDM has been discussed in many studies \[[@B11],[@B12]\]. However, the results were inconsistent. Therefore, we conducted a meta-analysis of studies on the *IGF2BP2* polymorphism with the aim of providing a more comprehensive summary of currently available research to evaluate the relationship between the *IGF2BP2* rs4402960 polymorphism and GDM risk.

Methods {#sec2}
=======

Study subjects {#sec2-1}
--------------

Between January 2014 and December 2018, 1521 singleton pregnant women were enrolled in the present study in the Department of Obstetrics, at the First Affiliated Hospital of China Medical University. All participants were provided with written informed consent and the study protocol was approved by the Medical Ethics Review Board of China Medical University (Shenyang, Liaoning, China).

Included GDM cases were identified after a glucose challenge test between weeks 24 and 28 of gestation. Participants were not eligible if they had a history of diabetes (including GDM in previous pregnancies). The control group consisted of 1216 middle-aged (18--45 years) non-diabetic Chinese women from the prospective hospital-based cohort \[[@B13]\]. We excluded those who presenting with maternal-related abnormalities, mothers with a history of drug abuse and depression, carriers of a blood-transmitted infectious disease, hypertension, and cardiovascular diseases.

All pregnant women were screened for GDM at 24--28 gestation weeks with a 75 g, 2 h oral glucose tolerance test. GDM was defined according to the International Association of Diabetes and Pregnancy Study Groups \[[@B14]\]. A diagnosis of GDM was made when one or more of the test parameters equaled or exceeded the following cut points: fasting: 5.1 mmol/l, 1-h: 10.0 mmol/l, or 2-h: 8.5 mmol/l. We also measured anthropometric parameters such as weight and height. Body mass index (BMI) was calculated. We also recorded maternal age, gravida, parity, family history of diabetes, and lipid profile.

Genotyping {#sec2-2}
----------

About 5 ml blood sample was collected from each participant. DNA was extracted with standard proteinase K digestion, followed by phenol--chloroform extraction and ethanol precipitation.

Genotyping of IGF2BP2 rs4402960 was performed with the Taqman allelic discrimination assays using ABI 7500 Real Time PCR (Applied Biosystems, Foster City, CA). All primers and probes were designed by Applied Biosystems (Foster City, CA). The primers sequence were 5′-GGAGCAGTAAGGTAGGATGGACAGTAGATT-3′ (forward) and 5′-AAGATACTGATTGTG TTTGCAAACATGCCC-3′ (reverse). Assay ID is C\_\_2165199_10, and context sequence is AGTAAGGTAGGATGGACAGTAGATT\[G/T\]AAGATACTGATTGTGTTTGCAAACA. The reaction mix included 10 μl DNA, 25 μl master mix (Applied Biosystems), 2.5 μl probe, and 12.5 μl sterile water in a final volume of 50 μl. PCR conditions comprised an initial denaturing step at 95°C for 10 min, followed by 45 cycles of 92°C for 30 s, with a final extension at 60°C for 1 min. PCR plates were read on an ABI PRISM 7900 instrument (Applied Biosystems). Two authors (G.S. and G.Z.) independently reviewed the genotyping results and input data.

Meta-analysis {#sec2-3}
-------------

Two examiners (J.L. and G.S.) independently searched for the significant studies in databases, including PubMed, Web of science, EMBASE, and Scopus on March 15, 2020. The search terms are the 'gestational diabetes mellitus', 'polymorphism/variant/mutation/', and '*IGF2BP2'*. Original studies were eligible if they met the following criteria: (I) case-control studies; (II) literatures on associations between *IGF2BP2* rs4402960 polymorphism and GDM; (III) results were denoted as odds ratio (OR) with 95% confidence intervals (CI). Original studies were ineligible if they: (I) were reviews, letters, or case reports; (II) did not contain outcomes which can be converted to OR and 95% CI; (III) included control group that was not involved with healthy women; (IV) were laboratory studies with animals. For duplicate publications, we only included the study with the largest sample size for analyses.

Two researchers (J.L. and G.Z.) carried out data extraction independently. If there were disagreements, they discussed and reached a consensus with the help from a third reviewer (TM). The data contained the first author, publication year, ethnicity, control source, genotyping method, genotype distribution in case and control groups. The Newcastle--Ottawa Scale (NOS) was used to assess the quality of all studies included. The NOS quality score ranges from 0 to 9 stars. Two authors independently assessed the quality of the studies included. Disagreements were resolved by discussion.

Statistical analysis {#sec2-4}
--------------------

Chi-square test was used to compare Allele/genotype frequencies between GDM and control groups. The strength of association between *IGF2BP2* rs4402960 polymorphism and GDM risk was assessed by calculating the OR with 95% CI. We calculated the OR by genotype and allele model comparisons of *IGF2BP2* rs4402960 polymorphism between cases and controls. The *P* value for Hardy--Weinberg equilibrium (HWE) was calculated in the control group using the chi-square test. Heterogeneity was assessed by using the *I*^2^ statistics. If there was no heterogeneity (*P*\>0.1 or *I*^2^\<50%), a fixed-effects model was used to estimate the pooled OR; otherwise, a random-effects model was utilized. Subgroup stratified analysis was performed using genotyping method (TaqMan assay or PCR), ethnicity (Caucasian or Asian), and control source (hospital-based or population-based). Study effects, such as publication bias, were evaluated with Egger's tests and a *P* value of \< 0.1 was considered statistically significant for asymmetry. Sensitivity analyses were directed to assess the influence of individual study on the overall estimate. Statistical analyses were performed with Stata (version 14.0; StataCorp, College Station, TX). The TSA (version 0.9.5.10, <http://www.ctu.dk/tsa/>) was conducted to maintain a 95% confidence interval, a 20% relative risk reduction, overall 5% risk of a type I error and 20% of the type II error (a power of 80%) in this study to reduce the risk of type I error.

Results {#sec3}
=======

Case--control study {#sec3-1}
-------------------

In total, 305 patients with GDM and 1216 controls participated in the present study. The baselines of characteristics of participants are shown in [Table 1](#T1){ref-type="table"}. Compared to the control groups, there was no difference in the maternal age, height, weight, pre-pregnancy BMI, gravida, parity, family history of diabetes, and low-density lipoprotein cholesterol (*P*\>0.05). There were significant differences between the two groups with respect to triglyceride, total cholesterol, and high-density lipoprotein cholesterol (*P*\<0.05). There was no difference in genotype frequencies between GDM and controls groups in *IGF2BP2*. Meanwhile, there was no significant susceptibility for rs4402960 polymorphism with GDM risk within five genetic models (all *P*\>0.05; [Table 2](#T2){ref-type="table"}).

###### Table 1 Clinical characteristics of pregnant women enrolled in the study

                                                                                   GDM (*n*=305)    Control (*n*=1216)   *P*
  -------------------------------------------------------------------------------- ---------------- -------------------- -------
  Maternal age (years)                                                             32.13 ± 3.04     32.13 ± 3.04         0.985
  Height (m)                                                                       1.63 ± 0.04      1.63 ± 0.05          0.303
  Weight (kg)                                                                      60.4 ± 7.24      59.8 ± 7.63          0.195
  Pre-pregnancy BMI (kg/m2)                                                        22.85 ± 3.06     22.69 ± 3.08         0.417
  Gravida                                                                          1 (1--2)         1 (1--2)             0.370
  Parity                                                                           0 (0--1)         0 (0--1)             0.994
  Family history of diabetes                                                       20 (7%)          64 (5%)              0.376
  Triglyceride (mg/dl)[\*](#T1TFN1){ref-type="table-fn"}                           232.53 ± 61.48   223.83 ± 62.16       0.029
  Total cholesterol (mg/dl)[\*](#T1TFN1){ref-type="table-fn"}                      241.06 ± 29.44   236.87 ± 30.67       0.032
  High-density lipoprotein cholesterol (mg/dl)[\*](#T1TFN1){ref-type="table-fn"}   67.98 ± 8.93     69.18 ± 7.09         0.013
  Low-density lipoprotein cholesterol (mg/dl)[\*](#T1TFN1){ref-type="table-fn"}    129.35 ± 22.02   131.44 ± 22.19       0.141

BMI, body mass index.

Maternal age, height, weight, and pre-pregnancy BMI were expressed as the mean ± standard deviation.

Gravida and parity were expressed as the median and interquartile ranges (interquartile ranges: the range of values lying between 25th and 75th centiles.

: test from each participant before 19 weeks + 6 days.

###### Genotype frequencies and analysis of *IGF2BP2* rs4402960 in Chinese population

       *n* (%)     *P*         Comparison   Type of model    OR (95% CI)    *P*                 
  ---- ----------- ----------- ------------ ---------------- -------------- ------------------- -------
  GG   168 (55%)   608 (50%)   0.179        T vs. G allele   Allele         0.83 (0.68--1.01)   0.060
  GT   115 (38%)   488 (40%)                TT+GT vs. GG     Dominant       0.82 (0.63--1.05)   0.112
  TT   22 (7%)     120 (10%)                TT vs. GG+GT     Recessive      0.71 (0.44--1.14)   0.154
                                            TT vs. GT        Heterozygous   0.85 (0.65--1.11)   0.322
                                            TT vs. GG        Homozygous     0.66 (0.41--1.08)   0.096

Abbreviations: CI, confidence interval; OR, odds ratio.

Literature search {#sec3-2}
-----------------

About 64 potentially eligible studies were retrieved. After application of the criteria, six studies were kept ([Figure 1](#F1){ref-type="fig"}). Characteristics of the seven studies, including ours, are shown in [Table 3](#T3){ref-type="table"}. The published year ranged from 2009 to 2020. The subjects in four were Asians, and Caucasians in three studies. Six were hospital-based design, only one was population-based design. Five studies used TaqMan assay, and two studies used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). NOS scores were between six and eight (details are shown in the **Supplementary Material**). A total of 8346 subjects were involved, including 2720 GDM patients and 5626 healthy women. All *P* values of HWE were more than 0.05.

![Flow chart of study selection](bsr-40-bsr20200990-g1){#F1}

###### Characteristics of 2720 gestational diabetes mellitus cases and 5626 controls included in this meta-analysis

  First author    Year   Country   Control source     Genotyping method   NOS Score   Case (*n*)   Control (*n*)   HWE (*P*)                                   
  --------------- ------ --------- ------------------ ------------------- ----------- ------------ --------------- ----------- ----- ------ ------ ----- ----- -------
  Lauenborg       2009   Denmark   Hospital-based     TaqMan assay        6           274          115             132         27    2334   1138   972   224   0.433
  Cho             2009   Korea     Population-based   TaqMan assay        6           857          389             365         103   627    313    257   57    0.685
  Wang            2011   China     Hospital-based     TaqMan assay        8           705          371             278         56    1025   605    361   59    0.596
  Chon            2013   Korea     Hospital-based     PCR-RFLP            6           94           57              30          7     41     15     24    2     0.053
  Popova          2017   Russia    Hospital-based     PCR-RFLP            7           278          120             134         24    179    77     76    26    0.310
  Tarnowski       2019   Poland    Hospital-based     TaqMan assay        7           207          105             76          26    204    89     93    22    0.753
  Current study   2020   China     Hospital-based     TaqMan assay        6           305          168             115         22    1216   608    488   120   0.131

Abbreviations: HWE, Hardy--Weinberg equilibrium; NOS, Newcastle--Ottawa Scale; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

Quantitative synthesis {#sec3-3}
----------------------

There was no statistically significant association between *IGF2BP2* rs4402960 polymorphism and GDM within five genetic models as shown in [Table 4:](#T4){ref-type="table"} allele (OR = 1.01, 95% CI = 0.86--1.18), dominant (OR = 1.00, 95% CI = 0.81--1.24), recessive (OR = 1.08, 95% CI = 0.91--1.29), heterozygous (OR = 0.99, 95% CI = 0.80--1.24), and homozygous models (OR = 1.06, 95% CI = 0.78--1.42). Subgroup analysis was conducted to reveal some details regarding potential associations between *IGF2BP2* rs4402960 polymorphism and GDM risk. No association was observed in five genetic models in each subgroup ([Table 5](#T5){ref-type="table"} and [Figures 2](#F2){ref-type="fig"}--[6](#F6){ref-type="fig"}).

![Forest plot for the association between *IGF2BP2* rs4402960 polymorphism and GDM risk using ethnicity subgroup analysis in the allele model (T vs. G allele)](bsr-40-bsr20200990-g2){#F2}

![Forest plot for the association between *IGF2BP2* rs4402960 polymorphism and GDM risk using ethnicity subgroup analysis in the dominant model (TT+GT vs. GG)](bsr-40-bsr20200990-g3){#F3}

![Forest plot for the association between *IGF2BP2* rs4402960 polymorphism and GDM risk using ethnicity subgroup analysis in the recessive model (TT vs. GG+GT)](bsr-40-bsr20200990-g4){#F4}

![Forest plot for the association between *IGF2BP2* rs4402960 polymorphism and GDM risk using ethnicity subgroup analysis in the heterozygous model (TT vs. GT)](bsr-40-bsr20200990-g5){#F5}

![Forest plot for the association between *IGF2BP2* rs4402960 polymorphism and GDM risk using ethnicity subgroup analysis in the homozygous model (TT vs. GG)](bsr-40-bsr20200990-g6){#F6}

###### Meta-analysis of association between *IGF2BP2* rs4402960 polymorphisms and risk of gestational diabetes mellitus

  Comparison       Type of model   Test of association   Test of heterogeneity   Statistical model   Test of publication bias Egger\'s, *P* value   Sensitivity analysis                               
  ---------------- --------------- --------------------- ----------------------- ------------------- ---------------------------------------------- ---------------------- ------- ------------------- -------------------
  T vs. G allele   Allele          1.01 (0.86--1.18)     0.950                   71.4                0.002                                          Random                 0.072   0.96 (0.80--1.14)   1.06 (0.91--1.23)
  TT+GT vs. GG     Dominant        1.00 (0.81--1.24)     0.986                   73.3                0.001                                          Random                 0.072   0.94 (0.73--1.20)   1.07 (0.89--1.28)
  TT vs. GG+GT     Recessive       1.08 (0.91--1.29)     0.368                   49.9                0.062                                          Fixed                  0.368   0.99 (0.81--1.22)   1.17 (0.97--1.41)
  TT vs. GT        Heterozygous    0.99 (0.80--1.24)     0.964                   71.9                0.002                                          Random                 0.055   0.93 (0.72--1.20)   1.08 (0.90--1.28)
  TT vs. GG        Homozygous      1.06 (0.78--1.42)     0.718                   55.4                0.036                                          Random                 0.368   0.97 (0.70--1.34)   1.18 (0.90--1.55)

Abbreviations: CI, confidence interval; OR, odds ratio.

###### Subgroup analysis of the associations of *IGF2BP2* rs4402960 (G\>T) polymorphisms with gestational diabetes mellitus

  Subgroup             *N*   Allele model (T vs. G allele)   Dominant model (TT+GT vs. GG)   Recessive model (TT vs. GG+GT)   Heterozygous model (TT vs. GT)   Homozygous model (TT vs. GG)                                                                                                                                                   
  -------------------- ----- ------------------------------- ------------------------------- -------------------------------- -------------------------------- ------------------------------ ------- ------ ------- ------------------- ------- ------ ------- ------------------- ------- ------ ------- ------------------- ------- ------ -------
  Genotyping method                                                                                                                                                                                                                                                                                                                           
    TaqMan assay       5     1.07 (0.91--1.26)               0.410                           71.7                             0.007                            1.08 (0.87--1.33)              0.491   72.0   0.006   1.15 (0.96--1.38)   0.135   37.3   0.173   1.06 (0.87--1.30)   0.552   67.4   0.015   1.16 (0.86--1.56)   0.321   54.6   0.066
    PCR-RFLP           2     0.78 (0.55--1.11)               0.164                           33.1                             0.222                            0.65 (0.25--1.67)              0.368   80.4   0.024   0.64 (0.37--1.10)   0.107   28.6   0.237   0.64 (0.19--2.14)   0.468   86.8   0.006   0.63 (0.35--1.12)   0.115   0      0.628
  Ethnicity                                                                                                                                                                                                                                                                                                                                   
    Caucasian          3     0.99 (0.80--1.23)               0.949                           52.9                             0.120                            1.02 (0.73--1.42)              0.906   65.8   0.053   0.91 (0.68--1.23)   0.550   46.8   0.153   1.04 (0.71--1.53)   0.837   71.4   0.030   0.93 (0.62--1.40)   0.722   38.3   0.198
    Asian              4     1.00 (0.78--1.28)               0.988                           81.5                             0.001                            0.96 (0.70--1.32)              0.810   82.0   0.001   1.19 (0.96--1.47)   0.120   50.9   0.106   0.94 (0.69--1.29)   0.722   79.0   0.003   1.16 (0.75--1.79)   0.510   64.8   0.036
  Control source                                                                                                                                                                                                                                                                                                                              
    Hospital-based     6     0.96 (0.80--1.16)               0.691                           73.4                             0.002                            0.94 (0.72--1.23)              0.675   76.7   0.001   0.99 (0.80--1.22)   0.953   48.2   0.086   0.95 (0.92--1.25)   0.703   76.3   0.001   0.97 (0.69--1.37)   0.874   54.0   0.054
    Population-based   1     1.19 (1.02--1.39)               0.031                           --                               --                               1.20 (0.98--1.47)              0.084   --     --      1.37 (0.97--1.92)   0.073   --     --      1.14 (0.92--1.42)   0.231   --     --      1.45 (1.02--2.08)   0.039   --     --

Abbreviations: CI, confidence interval; HWE, Hardy--Weinberg equilibrium; OR, odds ratio; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

Sensitivity analysis and publication bias {#sec3-4}
-----------------------------------------

There was no change after the deletion of any of the studies involved in the investigation, and no publication bias was detected ([Table 4](#T4){ref-type="table"}).

Trial sequential analysis {#sec3-5}
-------------------------

The cumulative *Z*-curve passed both the traditional boundary and required information size line, indicating sufficient proof of such association within the overall population ([Figure 7](#F7){ref-type="fig"}).

![Trial sequential analysis of GDM risk associated with *IGF2BP2* rs4402960 polymorphism in the recessive model](bsr-40-bsr20200990-g7){#F7}

Discussion {#sec4}
==========

Our case--control study did not reveal any association between *IGF2BP2* rs4402960 polymorphism and GDM risk. Further meta-analysis involving seven studies indicated that *IGF2BP2* rs4402960 polymorphism was not associated with GDM risk in overall population, Caucasian, or Asian under various genetic models. TSA analysis indicated that the pooled sample size was sufficient to support these null associations.

*IGF2BP2* belongs to a mRNA-binding protein family that plays important roles in RNA localization, stability, and translation \[[@B15]\]. *IGF2BP2* is highly expressed in pancreatic islets and binds to *IGF2*, which is an important growth and insulin signaling molecule \[[@B15]\]. Previous studies have shown the involvement of *IGF2BP2* gene polymorphism in attenuating the first phase of glucose-stimulated insulin secretion based on hyperglycaemic clamps, and the regulation of pancreatic β-cell function in Type 2 diabetes mellitus (T2DM) patients \[[@B16]\]. Therefore, the *IGF2BP2* rs4402960 polymorphism plays a role in pathogenesis of T2DM \[[@B17]\]. T2DM and GDM share a similar genetic background due to the common family history and similar features of impaired glucose tolerance between these two diseases \[[@B18]\]. Several T2DM-associated genetic variants have been confirmed to be associated with GDM, such as *TCF7L2* rs12255372 and *MTNR1B* rs10830963 \[[@B18]\] while the effects of other T2DM-associated genetic variants on GDM are controversial, such as *WFS1* rs10010131 and *ABCA1* rs1800977 \[[@B11],[@B19]\].

Early studies showed that *IGF2BP2* rs4402960 polymorphism was associated with GDM risk \[[@B11],[@B12],[@B20]\]. This finding has been cited in previously published reports \[[@B18],[@B21]\]. However, recent studies revealed there was no association between *IGF2BP2* rs4402960 polymorphism with GDM \[[@B10],[@B22]\]. Results reported to date are inconsistent. This could be due to limited statistical power with individual studies having relatively small sample sizes and the analysis of a specific ethnicity. For many of these studies, meta-analysis was usually performed in terms of genetic association studies of complicated diseases. Therefore, to further investigate the influence of *IGF2BP2* rs4402960 polymorphism on GDM risk, a meta-analysis of six previously published reports in combination with the present results of the case--control study was conducted. As far as we know, this is the first meta-analysis to date comprehensively quantified the association between the *IGF2BP2* and GDM risk.

However, meta-analysis has its potential limitation, resulting in spuriously overestimated (type I errors) or spuriously underestimated (type II errors) effects \[[@B23]\]. As a complement of meta-analysis, TSA was designed. TSA could reduce the risk of type I error by estimation of required information size with an adjusted threshold for statistical significance, and estimate whether further additional trials are needed \[[@B24]\]. If the cumulative *Z*-curve touches the trial sequential monitoring boundary, the futility boundary, or the required information size line, it shows firm evidence for such study. If not, additional studies are necessary to reach a consistent conclusion \[[@B24]\].

In our TSA results, the cumulative *Z*-curve crosses the traditional boundary using the Cho, Lauenborg, Wang, and Chon's studies \[[@B11],[@B12],[@B20],[@B25]\]. However, sample size of these four studies is not large enough. Two former meta-analyses ended up with the false positive conclusion due to the earlier publish time with insufficient sample size \[[@B21],[@B26]\]. Utilizing the data reported in recent studies, the cumulative *Z*-curve goes back to the zone between two traditional boundaries, then crosses the futility boundary and reaches the required information size line. Until now, there is sufficient evidence to support the null association between *IGF2BP2* rs4402960 polymorphism and GDM risk. This trend of cumulative *Z*-curve explains the TSA advantage, which helps us avoid reaching a premature statistical significance conclusion \[[@B23]\].

Limitation {#sec4-1}
----------

There were limitations in the present study. First, the sample size in each subgroup was small. Second, there was no study that includes the Blacks or Hispanics.

Conclusion {#sec5}
==========

This meta-analysis provides sufficient statistical evidence indicating null association between *IGF2BP2* rs4402960 polymorphism and GDM risk.
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